Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03156244 · ClinicalTrials.gov registry record

Using PROMIS as Part of Routine Clinical Care for Racially Diverse Prostate and Bladder Cancer Patients

A clinical trial of Prostate Cancer and Bladder Cancer, sponsored by UNC Lineberger Comprehensive Cancer Center.

Completed
Registry status
80
Enrollment target
1
Study location

NCT03156244 is a study of Prostate Cancer and Bladder Cancer that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 80 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03156244, a study of Prostate Cancer and Bladder Cancer, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.

COMPLETED
Registry status
80 participants
Enrollment target
1
Study location

Study Summary

In this pilot study, a total of 80 patients with prostate or bladder cancer (40 black, 40 white) will complete 3 patient-reported outcome (PRO) surveys: baseline (pre-treatment), during treatment, and after treatment. The overall goal of this study is to assess whether collecting patient-reported data is feasible as part of clinical care of cancer patients, and whether these data are useful for clinicians and patients. Among these 80 patients, those who agree will also undergo a semi-structured interview to assess value of HRQOL assessment at the end of the study. Of specific interest is an evaluation of whether feasibility and perceived value differ between black and white participants.

Study Locations (1)

North Carolina

  • Becky Green - Chapel Hill

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2017-05-08
Est. Completion 2018-05-05

What the Registry Record Tells You About NCT03156244

The ClinicalTrials.gov registry entry for NCT03156244 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (87% lower). The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 0 interventions.

NCT03156244 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT03156244 about?

NCT03156244 is a clinical study titled "Using PROMIS as Part of Routine Clinical Care for Racially Diverse Prostate and Bladder Cancer Patients". In this pilot study, a total of 80 patients with prostate or bladder cancer (40 black, 40 white) will complete 3 patient-reported outcome (PRO) surveys: baseline (pre-treatment), during treatment, and after treatment. The overall goal of this study is to assess whether collecting patient-reported da...

What is the current status of trial NCT03156244?

This trial is currently completed. The enrollment target is 80 participants. The study started on 2017-05-08. Estimated completion is 2018-05-05.

What conditions does trial NCT03156244 study?

This clinical trial studies the following conditions: Prostate Cancer, Bladder Cancer.

Who is sponsoring clinical trial NCT03156244?

This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03156244 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.